Start here if you're new
what it is
Allogene is trying to turn 4 cell therapy programs into cancer and autoimmune treatments you can get off the shelf.
how it gets paid
Last year Allogene Therapeutic made $0 in revenue.
why revenue is a footnote
Clinical-stage biotech — the income statement is R&D and G&A, not product sales. Compare cash runway and trial milestones instead of YoY “revenue growth.”
what just happened
Allogene posted $0 revenue again, while latest-quarter EPS landed at -$0.70.
At a glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
-$1.27 fy2024 eps est
$0M fy2024 rev est
1.3 beta
xvary composite: 33/100 — weak
What they do
Allogene is trying to turn 4 cell therapy programs into cancer and autoimmune treatments you can get off the shelf.
You are buying 4 collaboration agreements and 229 employees, not a sales machine. That is the whole point. If partners keep funding the work, you get a shot at 4 programs without paying for the whole lab.
How they make money
$0
annual revenue · revenue declined -100.0% last year
The products that matter
allogeneic CAR-T therapy platform
AlloCAR T Platform
$0 revenue today
this is the whole story right now: a platform carrying a $585M equity value despite producing $0 in current revenue. if the platform works, the valuation can look small. if it does not, there is not much underneath it.
entire thesis
phase 1/2 lymphoma program
ALLO-501A
ALPHA2 trial · readouts due through 2026
this is the lead clinical asset and the nearest shot at proving the model. with $0 product revenue elsewhere, one credible readout can dominate the stock for months.
lead catalyst
phase 1/2 solid tumor program
ALLO-316
TRAVERSE trial · earlier-stage bet
this pushes the story beyond lymphoma into renal cell carcinoma, but it is earlier and less proven. you are getting another path to upside, not a backstop.
second readout
Key numbers
$585M
market cap
You are paying $585M for a company with $0 revenue. That is a pure trial-data price.
$77M
debt
The company carries $77M of long-term debt. That is real pressure when sales are $0.
1.3
beta
A 1.3 beta means the stock has swung about 30% more than the market on average.
229
employees
229 employees have to run the whole operation. That is lean for 4 active programs.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $77M (12% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ALLO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Allogene posted $0 revenue again, while latest-quarter EPS landed at -$0.70.
EDGAR shows annual revenue at $0 and the latest quarter at $0 revenue. You are buying clinical shots on goal, not a business with sales.
$0M
revenue
-$0.70
eps
100.0%
revenue vs. last year
revenue
The number that mattered was $0 revenue. There is no sales cushion, so trial news does the pricing.
source: EDGAR SEC filing
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is clinical failure in ALLO-501A or ALLO-316. this is a $585M stock with $0 revenue, so almost all of the value is attached to proof that has not arrived yet.
med
clinical failure in the lead programs
ALLO-501A and ALLO-316 are the visible pillars of the story. if either shows weak efficacy or a safety issue, there is no operating business underneath to absorb the hit.
this lands on a company with $0 revenue today. disappointing data would pressure sentiment and valuation at the same time.
med
cash burn before the platform is proven
the company is still funding R&D and operations without product sales, while carrying $77M in long-term debt and a C++ balance sheet grade. in biotech, time is an expense line.
if the runway tightens before key 2026 readouts, you are looking at dilution risk on top of clinical risk.
med
competition can shrink the payoff even if the science works
allogene is chasing difficult oncology markets without commercial scale today. larger rivals can have an advantage in manufacturing, partnerships, and market access.
positive data would help. it would not guarantee that ALLO captures the full commercial prize investors are hoping for.
all three risks converge on the same math: a company with $0 revenue and $585M of equity value. if financing slips or the readouts disappoint, most of the current valuation has little operating support underneath it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
checkpoint
march 12, 2026 earnings
for ALLO, this is a cash-runway update wearing an earnings label. with $0 revenue, you care more about funding durability than top-line growth.
pipeline
ALLO-501A and ALLO-316 readouts through 2026
ALPHA2 and TRAVERSE are the catalysts that can validate the platform or remind the market this is still a theory with a ticker.
balance sheet
cash runway versus $77M in debt
a C++ balance sheet grade grade is survivable, not comfortable. if spending stays high while timelines slip, your leverage to good data shrinks.
funding risk
any sign the company needs capital before the next big readout
in a pre-revenue biotech, financing terms are part of the thesis. a raise after weak sentiment can hurt almost as much as a soft data point.
Analyst rankings
earnings predictability
50 / 100
in human-speak, analysts do not have a stable operating business to model here. expect revisions and sharp reactions.
beta
1.3
beta measures market sensitivity. this stock has moved more than the index, which fits a small-cap biotech with binary catalysts.
risk rank
5
safer than 5% of stocks. that is another way of saying the market sees a lot that can break before this becomes a real business.
source: institutional data
Institutional activity
institutional ownership data for ALLO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive